Biomaterial Database

Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis. 2013

Vidyut Bhatia, and Anupam Sibal, and Shilpy Rajgarhia

Apollo Center for Advanced Pediatrics, Indraprastha Apollo Hospital, New Delhi 110076, India.

Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported. We describe a case of CLV induced by rifampicin and pyrazinamide. A 14-year-old male diagnosed with disseminated tuberculosis developed purpuric lesions after 1.5 months of treatment. Histopathology was consistent with leukocytoclastic vasculitis. Skin lesion improved after cessation of the two drugs and treatment with corticosteroids.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D011239	Prednisolone	A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.	Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011718	Pyrazinamide	A pyrazine that is used therapeutically as an antitubercular agent.	Tisamid
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000995	Antitubercular Agents	Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.	Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012293	Rifampin	A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D014376	Tuberculosis	Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018366	Vasculitis, Leukocytoclastic, Cutaneous	Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases.	Angiitis, Hypersensitivity,Cutaneous Leukocytoclastic Vasculitis,Hypersensitivity Angiitis,Hypersensitivity Vasculitis,Vasculitis, Hypersensitivity,Allergic Cutaneous Angiitis,Allergic Cutaneous Vasculitis,Angiitis, Allergic Cutaneous,Cutaneous Allergic Vasculitis,Cutaneous Leukocytoclastic Angiitis,Vasculitis, Allergic Cutaneous,Allergic Cutaneous Angiitides,Allergic Cutaneous Vasculitides,Allergic Vasculitides, Cutaneous,Allergic Vasculitis, Cutaneous,Angiitides, Allergic Cutaneous,Angiitides, Cutaneous Leukocytoclastic,Angiitides, Hypersensitivity,Angiitis, Cutaneous Leukocytoclastic,Cutaneous Allergic Vasculitides,Cutaneous Angiitides, Allergic,Cutaneous Angiitis, Allergic,Cutaneous Leukocytoclastic Angiitides,Cutaneous Leukocytoclastic Vasculitides,Cutaneous Vasculitides, Allergic,Cutaneous Vasculitis, Allergic,Hypersensitivity Angiitides,Hypersensitivity Vasculitides,Leukocytoclastic Angiitides, Cutaneous,Leukocytoclastic Angiitis, Cutaneous,Leukocytoclastic Vasculitides, Cutaneous,Leukocytoclastic Vasculitis, Cutaneous,Vasculitides, Allergic Cutaneous,Vasculitides, Cutaneous Allergic,Vasculitides, Cutaneous Leukocytoclastic,Vasculitides, Hypersensitivity,Vasculitis, Cutaneous Allergic,Vasculitis, Cutaneous Leukocytoclastic